Neuromuscular

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how the COVID-19 pandemic has affected telemedicine.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending December 19, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 18, 2020.

Results of the phase 2 study support continued dose escalation of SRP-5051 and further clinical development.

The executive director of the Norman Fixel Institute for Neurological Diseases provided his thoughts on changing the perception of humanitarian device exemptions.

Results from the post-hoc analysis, funded by Mitsubishi Tanabe Pharma America, were recently announced.

These data follow a recent announcement from Sio Gene Therapies that the first patient in the high-dose cohort has been dosed.

The novel gold nanocrystal suspension has also been shown to remyelinate chronic MS lesions.

Future studies are necessary to determine whether longer treatment of ezogabine can sustain the effects on excitability and slow disease progression.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 11, 2020.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases detailed the collaborative effort needed to see sustainable change in the approval system of neurological devices.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending December 5, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 4, 2020.

The chief medical advisor for the Muscular Dystrophy Association discussed the organization’s recent annual telethon and the efforts to inform the public about these diseases.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the role insurance companies play within the system for approving neurological devices for rare diseases.

Rozanolixizumab was associated with reductions in anti-acetylcholine receptor autoantibodies and was well tolerated across 2 dose levels with no new safety findings.

Here's what is coming soon to NeurologyLive.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the issues within the current system that prevent approvals for neurologic devices for rare diseases.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

Seelos Therapeutics will soon enroll patients in its phase 2b/3 trial of SLS-005 in amyotrophic lateral sclerosis.

The professor of neurology at the NYU Langone Grossman School of Medicine detailed the ways the COVID-19 pandemic impacted mental health of frontline clinicians.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.